Literature DB >> 15647636

Bacterial translocation and its consequences in patients with cirrhosis.

Carlos Guarner1, Germán Soriano.   

Abstract

Bacterial translocation is the passage of viable bacteria from the intestinal lumen to mesenteric lymph nodes and other extraintestinal sites. Spontaneous bacterial peritonitis is the main clinical consequence of bacterial translocation in cirrhosis. Translocation of bacterial products of viable or non-viable bacteria, such as endotoxin and/or bacterial DNA, through the intestinal wall could stimulate the immune system and the hyperdynamic circulatory state in cirrhosis with clinical consequences that are under evaluation. Bacterial translocation is currently considered the passage of viable gut flora across the intestinal barrier to extraluminal sites. Aerobic Gram-negative bacilli are the most common translocating bacteria. Intestinal bacterial overgrowth, impairment in permeability of the intestinal mucosal barrier, and deficiencies in local host immune defences are the major mechanisms postulated to favour bacterial translocation in cirrhosis. Bacterial translocation is a key step in the pathogenesis of spontaneous bacteraemia and spontaneous bacterial peritonitis in cirrhosis. Translocation of intestinal bacterial products from viable or non-viable bacteria, such as endotoxin and bacterial DNA, has recently been associated with pathophysiological events, such as activation of the immune system and derangement of the hyperdynamic circulatory status in cirrhosis. Clinical consequences of these effects of bacterial products are presently under investigation.

Entities:  

Mesh:

Year:  2005        PMID: 15647636     DOI: 10.1097/00042737-200501000-00006

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  41 in total

Review 1.  Clinical use of albumin in hepatology.

Authors:  Matteo Garcovich; Maria Assunta Zocco; Antonio Gasbarrini
Journal:  Blood Transfus       Date:  2009-10       Impact factor: 3.443

Review 2.  Probiotics in hepatology.

Authors:  Jan Lata; Jana Jurankova; Marcela Kopacova; Petr Vitek
Journal:  World J Gastroenterol       Date:  2011-06-28       Impact factor: 5.742

Review 3.  Gut microbiota-related complications in cirrhosis.

Authors:  Isabel Gómez-Hurtado; José Such; Yolanda Sanz; Rubén Francés
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

4.  Procalcitonin, and cytokines document a dynamic inflammatory state in non-infected cirrhotic patients with ascites.

Authors:  Bashar M Attar; Christopher M Moore; Magdalena George; Nicolae Ion-Nedelcu; Rafael Turbay; Annamma Zachariah; Guiliano Ramadori; Jawed Fareed; David H Van Thiel
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

5.  Influence of colonic dialysis using Chinese medicine on creatinine decomposition by intestinal bacteria in uremia rats.

Authors:  Haidong He; Meilin Shen; Weiqian Sun; Yuyan Tang; Xudong Xu; Yan Xie
Journal:  Am J Transl Res       Date:  2019-10-15       Impact factor: 4.060

6.  Spontaneous bacterial empyema in liver cirrhosis: an underdiagnosed pleural complication.

Authors:  Naglaa A H Allam
Journal:  Saudi J Gastroenterol       Date:  2008-01       Impact factor: 2.485

7.  Clinical features and prognosis of spontaneous bacterial peritonitis in korean patients with liver cirrhosis: a multicenter retrospective study.

Authors:  Jeong Heo; Yeon Seok Seo; Hyung Joon Yim; Taeho Hahn; Sang Hoon Park; Sang Hoon Ahn; Jun Yong Park; Ji Young Park; Moon Young Kim; Sung Keun Park; Mong Cho; Soon Ho Um; Kwang Hyub Han; Hong Soo Kim; Soon Koo Baik; Byung Ik Kim; Se Hyun Cho
Journal:  Gut Liver       Date:  2009-09-30       Impact factor: 4.519

8.  Presence of anti-microbial antibodies in liver cirrhosis--a tell-tale sign of compromised immunity?

Authors:  Maria Papp; Gary L Norman; Zsuzsanna Vitalis; Istvan Tornai; Istvan Altorjay; Ildiko Foldi; Miklos Udvardy; Zakera Shums; Tamas Dinya; Peter Orosz; Bela Lombay; Gabriella Par; Alajos Par; Gabor Veres; Timea Csak; Janos Osztovits; Ferenc Szalay; Peter Laszlo Lakatos
Journal:  PLoS One       Date:  2010-09-23       Impact factor: 3.240

9.  Hepatitis C comorbidities affecting the course and response to therapy.

Authors:  Abdel-Rahman El-Zayadi
Journal:  World J Gastroenterol       Date:  2009-10-28       Impact factor: 5.742

10.  Increased immunoglobulin A in alcoholic liver cirrhosis: exploring the response of B cells to Toll-like receptor 9 activation.

Authors:  B Massonnet; A Delwail; J-M Ayrault; C Chagneau-Derrode; J-C Lecron; C Silvain
Journal:  Clin Exp Immunol       Date:  2009-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.